Zymeworks (NASDAQ:ZYME) Stock Price Target Raised at Citizens Jmp

Zymeworks (NASDAQ:ZYME) had its price objective lifted by Citizens Jmp from $32.00 to $39.00 in a report published on Friday morning, Marketbeat Ratings reports. Citizens Jmp currently has a market outperform rating on the stock.

A number of other equities research analysts have also recently issued reports on ZYME. Weiss Ratings restated a “sell (d-)” rating on shares of Zymeworks in a report on Thursday, October 15th. Wells Fargo & Company boosted their price target on Zymeworks from $37.00 to $40.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Jefferies Financial Group reiterated a “buy” rating and issued a $52.00 price objective on shares of Zymeworks in a research report on Friday, October 23rd. HC Wainwright increased their price target on shares of Zymeworks from $55.00 to $56.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, TD Cowen increased their price target on Zymeworks from $34.00 to $39.00 and gave the company a “buy” rating in a research note on Tuesday. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

Zymeworks Price Performance

Zymeworks stock opened at $26.24 on Friday. Zymeworks has a 12 month low of $18.20 and a 12 month high of $31.97. The stock’s 50-day moving average is $27.32 and its 200-day moving average is $25.48. The company has a market cap of $1.81 billion, a price-to-earnings ratio of 50.46 and a beta of 1.32.

Zymeworks (NASDAQ:ZYME) last posted its quarterly earnings results on Monday, November 9th. The company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.27 by $0.01. Zymeworks had a net margin of 16.10% and a return on equity of 22.23%. The company had revenue of $512.92 million for the quarter, compared to the consensus estimate of $227.40 million. During the same period last year, the firm posted ($0.26) EPS. The company’s revenue for the quarter was up 828.7% on a year-over-year basis. Research analysts anticipate that Zymeworks will post 1.31 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Adam Schayowitz sold 13,832 shares of the stock in a transaction that occurred on Friday, October 9th. The stock was sold at an average price of $25.85, for a total transaction of $357,557.20. Following the completion of the sale, the executive vice president directly owned 23,205 shares of the company’s stock, valued at approximately $599,849.25. This trade represents a 37.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 37.73% of the company’s stock.

Institutional Investors Weigh In On Zymeworks

A number of large investors have recently added to or reduced their stakes in ZYME. BlackRock Inc. purchased a new position in shares of Zymeworks during the 2nd quarter valued at $111,122,000. Rubric Capital Management LP raised its holdings in Zymeworks by 21.7% during the 1st quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company’s stock valued at $175,280,000 after buying an additional 1,250,000 shares during the period. Fisher Asset Management LLC raised its position in Zymeworks by 759.9% in the 3rd quarter. Fisher Asset Management LLC now owns 608,612 shares of the company’s stock worth $16,122,000 after purchasing an additional 537,837 shares during the period. Assenagon Asset Management S.A. grew its stake in Zymeworks by 72.0% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,252,027 shares of the company’s stock worth $32,728,000 after acquiring an additional 524,041 shares in the last quarter. Finally, Deutsche Bank AG bought a new stake in Zymeworks during the 2nd quarter valued at $10,383,000. Institutional investors own 92.89% of the company’s stock.

Key Headlines Impacting Zymeworks

These are some of the ZYME headlines that stood out recently:

• Positive Sentiment: Citizens JMP raised its price target to $39 from $32 and assigned a “market outperform” rating, implying substantial upside from the referenced $26.24 share price. TickerReport article
• Positive Sentiment: A report linked Zymeworks’ improved outlook to a milestone payment and a profitable quarter. The company’s latest reported results also beat the cited EPS consensus slightly, while revenue was well above estimates—supportive news, though milestone revenue may not recur. Milestone Payment Lifts Zymeworks Stock Outlook After Profitable Quarter
• Negative Sentiment: HC Wainwright cut its estimates across several upcoming quarters, lowering its FY2026 EPS forecast to $1.19 from $1.51 and moving its FY2027 outlook from $1.32 profit to a projected $0.39 loss. The analyst retained a Buy rating and $56 target, but the revisions signal a less favorable earnings outlook beyond the recent quarter.

About Zymeworks

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.